Mechanism of Action
Receptor Subtype Pharmacology
GALR1 couples to Gi, inhibiting adenylyl cyclase and opening inwardly rectifying K+ channels, causing neuronal hyperpolarization and inhibition. GALR2 couples to Gq/G11, activating phospholipase C and increasing calcium, producing excitatory effects. GALR3 resembles GALR1 in Gi coupling. This divergence explains the complex and sometimes contradictory effects of galanin: GALR1 activation tends to be inhibitory (sedative, anti-nociceptive, anxiogenic), while GALR2 activation is often neuroprotective and anxiolytic.
Acetylcholine and Memory
Galanin is co-expressed in cholinergic neurons of the basal forebrain (medial septum, nucleus basalis of Meynert) and inhibits acetylcholine release via GALR1. In Alzheimer's disease, galanin fiber hyperinnervation of surviving cholinergic neurons may exacerbate cholinergic deficit. Galanin receptor antagonists enhance acetylcholine release and improve memory in rodent models, supporting a pro-cognitive role for GALR1 blockade.
Research Summary
Alzheimer's Disease
Active ResearchGalanin fiber sprouting in AD hippocampus (up to 400% increase) correlates with disease severity and cholinergic neuron loss. GALR1 antagonists improve memory consolidation and spatial navigation in aged and AD model rodents by releasing tonic inhibition of cholinergic neurons. GALR2 agonism shows neuroprotective effects in hippocampal cultures exposed to amyloid-beta. Clinical translation ongoing.
Pain and Spinal Cord
Active ResearchIntrathecal galanin reduces hyperalgesia and allodynia in chronic pain models via GALR1 inhibition of spinal nociceptive neurons. Paradoxically, spinal GALR2 activation can produce pronociceptive effects at high doses. Net analgesic effect is dose-dependent. Galanin is upregulated in dorsal root ganglia after nerve injury, suggesting endogenous anti-nociceptive role. GALR1-selective agonists are being developed as non-opioid analgesics.
Depression, Anxiety and Stress
Active ResearchGalanin in the locus coeruleus modulates norepinephrine release and stress resilience. Galanin overexpressing mice show depression-like behavior reversed by GALR1 antagonism. GALR2 activation in limbic regions produces antidepressant and anxiolytic effects. Galanin-NE interactions in LC are proposed as a key node in stress-induced affective disorders. Human polymorphisms in the galanin promoter associate with depression risk.
Calculate your Galanin dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Memory/cholinergic research | 1-3 nmol ICV injection in rodents | Single dose, pre- or post-training | Intracerebroventricular |
| Pain research (spinal) | 0.1-1 nmol intrathecal in rodents | Single dose | Intrathecal |
No approved human therapeutic. Galanin receptor-subtype-selective ligands are research tools for dissecting GALR1 vs GALR2/3 contributions in vivo.
Interactions
Safety Profile
Endogenous galanin is well tolerated. Research doses in animals: ICV galanin causes transient sedation, hypothermia, hypotension, and hyperphagia at high doses. Peripheral IV galanin produces vasodilation and mild hypotension. No human therapeutic safety data available. GALR1/2 ligand development programs focus on CNS-active compounds; peripherally restricted analgesics being explored for pain with fewer CNS effects.
References
- [1]Tatemoto K, et al. Galanin -- a novel biologically active peptide from porcine intestine. FEBS Lett. 1983;164(1):124-128.
- [2]Mufson EJ, et al. Galanin and the cholinergic system in Alzheimer's disease. Neuropeptides. 2005;39(3):233-237.
- [3]Holmes A, et al. Galanin GAL-R1 receptor null mutant mice display increased anxiety-like behavior. Neuropsychopharmacology. 2003;28(6):1031-1044.